Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

DSGN vs TBPH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TBPH Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–1 Matrix Metrics)

TBPH Overall Winner 6-Pillar Tally: DSGN 0 – 6 TBPH Matrix Metrics: DSGN 1 – 9 TBPH

As of Nov 16, 2026, Theravance Biopharma, Inc. (TBPH) is the stronger overall head-to-head candidate over Design Therapeutics, Inc. (DSGN) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). DSGN carries a Unified Composite Score of 49.9/100 (HOLD) at $9.94 (N/M Forward P/E, 0.0% operating margin), whereas TBPH carries 54.9/100 (HOLD) at $17.03 (13.4x Forward P/E, 8.9% operating margin).

  • Growth vs. Quality Trade-Off: TBPH earns the overall head-to-head edge with a stronger Unified Composite Score (54.9/100 HOLD vs. DSGN 49.9/100 HOLD) and 0.48β · 2% Vol risk profile, whereas DSGN leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: DSGN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.4); meanwhile TBPH trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 53.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DSGN vs TBPH
DSGN NASDAQ
Design Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$9.94
-5.06% 1D
Market Cap $677.5M
TTM Revenue $33,000
Forward P/E N/M
Beta / 30D Vol 1.32β · 61% Vol
Unified Composite Score
49.9 / 100 HOLD
Tech 55.0 Fund 56.0 Flow 63.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.7%), weak momentum, RSI 41
RSI-14: 41.4 · SMA20: $10.53 · SMA50: $11.59
TBPH NASDAQ Head-to-Head Winner
Theravance Biopharma, Inc.
Pharmaceutical Preparations
$17.03
+0.0% 1D
Market Cap $884.2M
TTM Revenue $104M
Forward P/E 13.4x
Beta / 30D Vol 0.48β · 2% Vol
Unified Composite Score
54.9 / 100 HOLD
Tech 65.0 Fund 52.0 Flow 50.0 Mom 35.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 53.6 · SMA20: $17.04 · SMA50: $16.96

6-Pillar Scorecard Institutional Category Breakdown (DSGN 0 – 6 TBPH)

Columns: Metric · DSGN · TBPH
1. Valuation Multiples TBPH
Forward P/E N/M 13.4x
Trailing P/E N/M 16.4x
PEG Ratio N/M N/M
EV / Revenue N/M 8.5x
2. Growth & Scale TBPH
Revenue Growth (YoY) +0.0% -20.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $33,000 $104M
Market Cap $677.5M $884.2M
3. Profitability & Quality TBPH
Gross Margin N/A 75.1%
Operating Margin 0.0% 8.9%
Net Profit Margin 0.0% 51.6%
Return on Equity (ROE) -36.9% 20.9%
4. Balance Sheet & Cash Flow TBPH
Cash Generation (TTM) -$59M $11M EBITDA
Cash Flow Margin N/A 10.6% EBITDA Mgn
Net Cash / Leverage $13M Net Cash $5.58 Book/Sh · 20.9% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning TBPH
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 92.0% (13th %ile) 55.0% (16th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat TBPH
OpEx & R&D Intensity N/A 66.2% of Rev ($69M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DSGN (1) vs TBPH (9)
Institutional Metric DSGN TBPH Criterion Row Edge
Market Capitalization
Scale
$677.5M $884.2M Larger Scale TBPH
Trailing P/E Ratio
Valuation
N/M 16.4x Lower Multiple TBPH
Forward P/E Ratio
Valuation
N/M 13.4x Lower Multiple TBPH
Revenue Growth (YoY)
Growth
+0.0% -20.9% Higher Growth DSGN
Operating Margin (TTM)
Profitability
0.0% 8.9% Higher Margin TBPH
Net Profit Margin
Profitability
0.0% 51.6% Higher Margin TBPH
Return on Equity (ROE)
Capital Efficiency
-36.9% 20.9% Higher ROE TBPH
52-Week Range Position
Momentum
30% ($7–$17) 50% ($13–$21) Stronger Trend TBPH
Beta / 30D Volatility
Risk Regime
1.32β · 61% Vol 0.48β · 2% Vol Lower Realized Risk TBPH
Unified Institutional Score
Composite Signal
49.9 / 100 (HOLD) 54.9 / 100 (HOLD) Higher Composite TBPH
Trailing 12M Revenue (USD)
Operating Scale
$33,000 $104M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 75.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 8.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$59M ($13M Net Cash) $11M EBITDA ($5.58 Book/Sh · 20.9% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TBPH +18.96 pp
DSGN: -18.84% · TBPH: +0.12%
3M Horizon TBPH +8.91 pp
DSGN: -10.3% · TBPH: -1.39%
6M Horizon DSGN +5.58 pp
DSGN: +19.88% · TBPH: +14.3%
1Y Horizon DSGN +80.2 pp
DSGN: +75.07% · TBPH: -5.13%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DSGN vs TBPH. Trailing 12-month operating profitability (DSGN 0.0% vs TBPH 8.9%) and valuation multiples (DSGN N/M vs TBPH 13.4x Forward P/E) are benchmarked directly in Pillar 4 below.

DSGN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$33,000
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-36.9% · N/M
TBPH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$104M
Gross Margin75.1%
Op. Margin8.9%
ROE / Fwd P/E20.9% · 13.4x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DSGN BREAKDOWN
139d in phase · OBV NEUTRAL
Current IV 92.0%
IV Percentile 13th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact DSGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TBPH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 55.0%
IV Percentile 16th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TBPH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DSGN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $677.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
TBPH Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $884.2M market capitalization and 8.9% operating margin.
OpEx & R&D Reinvestment 66.2% of Rev ($69M)
90D Engineering Disclosures 0 Published

Investor FAQ DSGN vs TBPH Key Questions & Quantitative Answers

As of Nov 16, 2026, Theravance Biopharma, Inc. (TBPH) is the stronger overall head-to-head candidate over Design Therapeutics, Inc. (DSGN) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). DSGN carries a Unified Composite Score of 49.9/100 (HOLD) at $9.94 (N/M Forward P/E, 0.0% operating margin), whereas TBPH carries 54.9/100 (HOLD) at $17.03 (13.4x Forward P/E, 8.9% operating margin). Growth vs. Quality Trade-Off: TBPH earns the overall head-to-head edge with a stronger Unified Composite Score (54.9/100 HOLD vs. DSGN 49.9/100 HOLD) and 0.48β · 2% Vol risk profile, whereas DSGN leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: DSGN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.4); meanwhile TBPH trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 53.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TBPH leads the Growth & Scale pillar: DSGN posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $33,000 TTM revenue (N/A gross margin, 0.0% operating margin), compared with TBPH at -20.9% YoY revenue growth and +0.0% YoY earnings growth on $104M TTM revenue (75.1% gross margin, 8.9% operating margin). On trailing 12-month operating scale, DSGN generates $33,000 in USD-normalized revenue versus $104M for TBPH. In operating R&D and SG&A reinvestment, DSGN deploys N/A (0 90-day corporate R&D disclosures) versus 66.2% of Rev ($69M) (0 disclosures) for TBPH.

TBPH screens cheaper on headline valuation multiples. DSGN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas TBPH trades at 13.4x Forward P/E, 16.4x Trailing P/E, N/M PEG, and 8.5x EV/Revenue (10.6% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DSGN (-36.9% ROE) versus TBPH (20.9% ROE) capital efficiency.

In options market volatility and institutional positioning, DSGN carries 92.0% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.32β · 61% Vol realized risk). By comparison, TBPH carries 55.0% implied volatility (16th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.48β · 2% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.